论文部分内容阅读
目的:探讨4种原料血浆制备的冷沉淀中部分凝血因子含量,为临床提供优质的冷沉淀制剂。方法:选取400ml ACD-B保存液全血20袋,将每袋400ml全血分为2份,制备成悬浮红细胞和滤白悬浮红细胞。制备悬浮红细胞得到的100ml血浆又分2份,制备成新鲜冰冻血浆(FFP)和新鲜病毒灭活冰冻血浆(灭活FFP);制备滤白悬浮红细胞得到的100ml新鲜滤白血浆又分2份,制备成新鲜滤白冰冻血浆(滤白FFP)和新鲜滤白病毒灭活冰冻血浆(滤白灭活FFP)。4种血浆在液体状态下留样,冰冻,备检。1周后将4种冰冻血浆对应制备成4种冷沉淀:FFP冷沉淀、滤白冷沉淀、灭活冷沉淀、滤白灭活冷沉淀。冷沉淀冰冻1周后37℃度水浴溶化后留样。检测Ⅷ因子含量(FⅧ)及纤维蛋白原(Fg)含量。结果:FFP、灭活FFP、滤白FFP、滤白灭活FFP的FⅧ及Fg回收率依次为100%、89.8%、74.3%、50.1%和100%、89.5%、52.1%、48.3%。FFP冷沉淀、滤白冷沉淀、灭活冷沉淀、滤白灭活冷沉淀的FⅧ及Fg回收率依次为100%、89.7%、78.6%、48.1%和100%、91.7%、54.7%、50.8%。结论:不同原料血浆及其制备成的冷沉淀凝血因子回收率差别较大。制备冷沉淀时应优选原料血浆,保证输血疗效。
Objective: To investigate the contents of some clotting factors in cryoprecipitate prepared from plasma of four kinds of raw materials to provide high quality cryoprecipitate for clinical use. Methods: Totally 20 bags of whole blood were collected from 400ml ACD-B preservation solution, and 400ml whole blood was divided into 2 parts to prepare suspension erythrocytes and leucocyte suspension. 100 ml of plasma obtained from the preparation of the suspension erythrocytes was further divided into 2 portions to prepare fresh frozen plasma (FFP) and fresh virus inactivated frozen plasma (inactivated FFP); 100 ml of fresh white blood plasma obtained from the preparation of the white suspended erythrocytes was further divided into 2 portions, Prepared into fresh filtered white frozen plasma (FFP) and fresh filtered virus inactivated frozen plasma (FFP inactivated). Four kinds of plasma in the liquid state to stay kind, frozen, for inspection. After 1 week, four kinds of cryoprecipitate were prepared correspondingly to four kinds of frozen plasma: FFP cryoprecipitate, filtration and cryoprecipitation, inactivation of cryoprecipitate, filtration and inactivation of cryoprecipitate. Cryoprecipitate frozen after 1 week 37 ℃ water bath to dissolve samples. The contents of FⅧ and Fg were measured. Results: The FⅧ and Fg recoveries of FFP, FFP, FFP and FFP were 100%, 89.8%, 74.3%, 50.1% and 100%, 89.5%, 52.1% and 48.3%, respectively. The FⅧ and Fg recoveries of FFP cryoprecipitation, filtration-white cryoprecipitation, inactivation of cryoprecipitate and filtration-inactivated cryoprecipitate were 100%, 89.7%, 78.6%, 48.1% and 100%, 91.7%, 54.7% and 50.8, respectively %. Conclusion: Different raw materials of plasma and its preparation of cryoprecipitate coagulation factor recovery difference. Preparation of cryoprecipitate should be preferred raw material plasma, to ensure transfusion efficacy.